(ERF) Eurofins Scientific SE - Ratings and Ratios
Testing, Laboratory, Services, Analysis, Certification
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 30.6% |
| Value at Risk 5%th | 44.6% |
| Relative Tail Risk | -11.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.88 |
| Alpha | 24.63 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.451 |
| Beta | 0.075 |
| Beta Downside | 0.105 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.77% |
| Mean DD | 18.71% |
| Median DD | 18.53% |
Description: ERF Eurofins Scientific SE October 31, 2025
Eurofins Scientific SE (ticker ERF) is a Luxembourg-based, globally-operating provider of analytical testing and laboratory services across a broad portfolio that includes agroscience, food & feed safety, environmental monitoring, biopharma & clinical diagnostics, consumer product testing, cosmetics, electronics, forensic and genomics. Its business model is built on fee-for-service contracts and long-term regulatory compliance engagements, allowing the firm to capture recurring revenue from diverse, high-touch markets.
Key growth levers for Eurofins are the rising demand for ESG-related testing (e.g., sustainability certifications, microplastic analysis) and the expansion of outsourced biotech R&D, both of which have driven organic revenue growth of roughly 10% YoY in 2023, bringing total sales to about €6.5 billion. The company benefits from a high gross margin (~45%) typical of specialized lab services, and its decentralized acquisition strategy has historically delivered ~15% annual earnings-before-interest-tax-depreciation-amortisation (EBITDA) growth, albeit with integration risk. Macro-level drivers include tightening global food safety regulations, increased pharmaceutical outsourcing, and heightened consumer scrutiny of product claims.
For investors seeking a data-driven assessment of Eurofins’ valuation dynamics, a deeper dive on ValueRay’s platform can help surface comparable peer multiples and scenario-based forecasts without any sales pressure.
ERF Stock Overview
| Market Cap in USD | 12,235m |
| Sub-Industry | Biotechnology |
| IPO / Inception | |
| Return 12m vs S&P 500 | 13.8% |
| Analyst Rating | - |
ERF Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 1.02% |
| Yield on Cost 5y | 0.88% |
| Yield CAGR 5y | -9.74% |
| Payout Consistency | 79.2% |
| Payout Ratio | 26.4% |
ERF Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -2.79% |
| CAGR/Max DD Calmar Ratio | -0.08 |
| CAGR/Mean DD Pain Ratio | -0.15 |
| Current Volume | 189k |
| Average Volume | 246.7k |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (503.1m TTM) > 0 and > 6% of Revenue (6% = 628.0m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 4.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 5.10% (prev 9.67%; Δ -4.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 2.01b > Net Income 503.1m (YES >=105%, WARN >=100%) |
| Net Debt (3.36b) to EBITDA (2.17b) ratio: 1.55 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (188.5m) change vs 12m ago -4.61% (target <= -2.0% for YES) |
| Gross Margin 14.42% (prev 12.63%; Δ 1.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 97.48% (prev 89.74%; Δ 7.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.20 (EBITDA TTM 2.17b / Interest Expense TTM 221.7m) >= 6 (WARN >= 3) |
Altman Z'' 2.78
| (A) 0.05 = (Total Current Assets 2.62b - Total Current Liabilities 2.09b) / Total Assets 10.59b |
| (B) 0.27 = Retained Earnings (Balance) 2.81b / Total Assets 10.59b |
| (C) 0.11 = EBIT TTM 1.15b / Avg Total Assets 10.74b |
| (D) 0.82 = Book Value of Equity 4.86b / Total Liabilities 5.91b |
| Total Rating: 2.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.55
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 7.88% = 3.94 |
| 3. FCF Margin 10.46% = 2.62 |
| 4. Debt/Equity 0.89 = 2.12 |
| 5. Debt/Ebitda 1.55 = 0.87 |
| 6. ROIC - WACC (= 5.11)% = 6.39 |
| 7. RoE 9.84% = 0.82 |
| 8. Rev. Trend 14.82% = 1.11 |
| 9. EPS Trend 13.76% = 0.69 |
What is the price of ERF shares?
Over the past week, the price has changed by +1.24%, over one month by -6.08%, over three months by -12.80% and over the past year by +30.31%.
Is ERF a buy, sell or hold?
What are the forecasts/targets for the ERF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 64.4 | 9.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 61.4 | 4.5% |
ERF Fundamental Data Overview November 18, 2025
Market Cap EUR = 10.54b (10.54b EUR * 1.0 EUR.EUR)
P/E Trailing = 25.9736
P/E Forward = 13.5135
P/S = 1.4753
P/B = 2.2533
P/EG = 0.7147
Beta = 0.876
Revenue TTM = 10.47b EUR
EBIT TTM = 1.15b EUR
EBITDA TTM = 2.17b EUR
Long Term Debt = 3.58b EUR (from longTermDebt, last quarter)
Short Term Debt = 538.4m EUR (from shortTermDebt, last quarter)
Debt = 4.11b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.36b EUR (from netDebt column, last quarter)
Enterprise Value = 13.90b EUR (10.54b + Debt 4.11b - CCE 753.3m)
Interest Coverage Ratio = 5.20 (Ebit TTM 1.15b / Interest Expense TTM 221.7m)
FCF Yield = 7.88% (FCF TTM 1.10b / Enterprise Value 13.90b)
FCF Margin = 10.46% (FCF TTM 1.10b / Revenue TTM 10.47b)
Net Margin = 4.81% (Net Income TTM 503.1m / Revenue TTM 10.47b)
Gross Margin = 14.42% ((Revenue TTM 10.47b - Cost of Revenue TTM 8.96b) / Revenue TTM)
Gross Margin QoQ = 22.43% (prev 9.96%)
Tobins Q-Ratio = 1.31 (Enterprise Value 13.90b / Total Assets 10.59b)
Interest Expense / Debt = 1.67% (Interest Expense 68.6m / Debt 4.11b)
Taxrate = 28.79% (49.9m / 173.2m)
NOPAT = 820.8m (EBIT 1.15b * (1 - 28.79%))
Current Ratio = 1.26 (Total Current Assets 2.62b / Total Current Liabilities 2.09b)
Debt / Equity = 0.89 (Debt 4.11b / totalStockholderEquity, last quarter 4.64b)
Debt / EBITDA = 1.55 (Net Debt 3.36b / EBITDA 2.17b)
Debt / FCF = 3.07 (Net Debt 3.36b / FCF TTM 1.10b)
Total Stockholder Equity = 5.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.75% (Net Income 503.1m / Total Assets 10.59b)
RoE = 9.84% (Net Income TTM 503.1m / Total Stockholder Equity 5.11b)
RoCE = 13.26% (EBIT 1.15b / Capital Employed (Equity 5.11b + L.T.Debt 3.58b))
RoIC = 9.97% (NOPAT 820.8m / Invested Capital 8.24b)
WACC = 4.86% (E(10.54b)/V(14.65b) * Re(6.29%) + D(4.11b)/V(14.65b) * Rd(1.67%) * (1-Tc(0.29)))
Discount Rate = 6.29% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.33%
[DCF Debug] Terminal Value 78.26% ; FCFE base≈924.0m ; Y1≈922.1m ; Y5≈974.4m
Fair Price DCF = 97.34 (DCF Value 17.24b / Shares Outstanding 177.1m; 5y FCF grow -0.83% → 3.0% )
EPS Correlation: 13.76 | EPS CAGR: 211.2% | SUE: -4.0 | # QB: 0
Revenue Correlation: 14.82 | Revenue CAGR: 2.10% | SUE: -0.00 | # QB: 0